These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20204293)

  • 21. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression.
    Yen TC; See LC; Lai CH; Yah-Huei CW; Ng KK; Ma SY; Lin WJ; Chen JT; Chen WJ; Lai CR; Hsueh S
    J Nucl Med; 2004 Jan; 45(1):22-9. PubMed ID: 14734665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II.
    Ong LC; Jin Y; Song IC; Yu S; Zhang K; Chow PK
    Acta Radiol; 2008 Dec; 49(10):1145-53. PubMed ID: 18979289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET--initial experience.
    Tsujikawa T; Yoshida Y; Mori T; Kurokawa T; Fujibayashi Y; Kotsuji F; Okazawa H
    Radiology; 2008 Aug; 248(2):599-605. PubMed ID: 18539894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma.
    Kato H; Takita J; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K
    Anticancer Res; 2003; 23(4):3263-72. PubMed ID: 12926062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II.
    Hamada K; Tomita Y; Qiu Y; Zhang B; Ueda T; Myoui A; Higuchi I; Yoshikawa H; Aozasa K; Hatazawa J
    Ann Nucl Med; 2008 Oct; 22(8):699-705. PubMed ID: 18982473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of Glut-1 in primary and recurrent head and neck squamous cell carcinomas, and compared with 2-[18F]fluoro-2-deoxy-D-glucose accumulation in positron emission tomography.
    Li SJ; Guo W; Ren GX; Huang G; Chen T; Song SL
    Br J Oral Maxillofac Surg; 2008 Apr; 46(3):180-186. PubMed ID: 18093707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung.
    Mamede M; Higashi T; Kitaichi M; Ishizu K; Ishimori T; Nakamoto Y; Yanagihara K; Li M; Tanaka F; Wada H; Manabe T; Saga T
    Neoplasia; 2005 Apr; 7(4):369-79. PubMed ID: 15967114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging.
    Sharma P; Kumar R; Singh H; Jeph S; Sharma JB; Jain SK; Sharma DN; Bal C; Malhotra A
    Nucl Med Commun; 2012 Feb; 33(2):185-90. PubMed ID: 22107993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression.
    Yamada A; Oguchi K; Fukushima M; Imai Y; Kadoya M
    Ann Nucl Med; 2006 Nov; 20(9):597-604. PubMed ID: 17294670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas.
    Murakami M; Tsukada H; Shida M; Watanabe M; Maeda H; Koido S; Hirasawa T; Muramatsu T; Miyamoto T; Nasu S; Yasuda S; Kajiwara H; Yasuda M; Ide M
    Int J Gynecol Cancer; 2006; 16(2):854-60. PubMed ID: 16681773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of preoperative ¹⁸F-FDG PET/CT in uterine leiomyosarcoma.
    Park JY; Lee JW; Lee HJ; Lee JJ; Moon SH; Kang SY; Cheon GJ; Chung HH
    J Gynecol Oncol; 2017 May; 28(3):e28. PubMed ID: 28382795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ¹⁸FDG PET for grading malignancy in thymic epithelial tumors: significant differences in ¹⁸FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: preliminary study.
    Nakajo M; Kajiya Y; Tani A; Yoneda S; Shirahama H; Higashi M; Nakajo M
    Eur J Radiol; 2012 Jan; 81(1):146-51. PubMed ID: 20810231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High 18F-FDG uptake for uterine smooth muscle tumor of uncertain malignant potential.
    Zhang R; Tian X; Qin L; Lu D; Shen J
    Clin Nucl Med; 2015 Apr; 40(4):349-51. PubMed ID: 25674868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors.
    Koyama K; Okamura T; Kawabe J; Ozawa N; Torii K; Umesaki N; Miyama M; Ochi H; Yamada R
    J Nucl Med; 2003 Mar; 44(3):353-8. PubMed ID: 12621000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of fluorine-18 fluorodesoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas.
    Kasper B; Hohenberger P; Strauss LG; Dimitrakopoulou-Strauss A
    Hell J Nucl Med; 2010; 13(1):40-4. PubMed ID: 20411170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
    Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
    J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.
    Avril N; Menzel M; Dose J; Schelling M; Weber W; Jänicke F; Nathrath W; Schwaiger M
    J Nucl Med; 2001 Jan; 42(1):9-16. PubMed ID: 11197987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffusion-weighted MRI and 18F-FDG-PET/CT imaging: competition or synergy as diagnostic methods to manage sarcoma of the uterus? A systematic review of the literature.
    Dubreuil J; Tordo J; Rubello D; Giammarile F; Skanjeti A
    Nucl Med Commun; 2017 Jan; 38(1):84-90. PubMed ID: 27898647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative [
    Lee JW; Park JY; Lee HJ; Lee JJ; Moon SH; Kang SY; Cheon GJ; Chung HH
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1309-1316. PubMed ID: 29492644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of 18F-FDG PET/CT imaging in the staging, restaging, monitoring of response to therapy and surveillance of uterine leiomyosarcomas.
    Bélissant O; Champion L; Thevenet H; Weinmann P; Alberini JL
    Nucl Med Commun; 2018 Jul; 39(7):652-658. PubMed ID: 29683931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.